Norditropin Enhances Height and Psychosocial Well-being in American Males with ISS: Trial Results
Reading Time: 2 minutes Introduction Idiopathic short stature (ISS) represents a significant concern for many families, particularly when it affects the psychological well-being and social integration of young males. Norditropin, a recombinant human growth hormone, has emerged as a potential therapeutic agent in managing ISS. This article delves into the findings of a recent multi-center, double-blind trial that assessed the efficacy of Norditropin in American males diagnosed with ISS, offering valuable insights into its potential benefits and implications for clinical practice. Study Design and Methodology The trial, conducted across multiple centers in the United States, involved 250 male participants aged 4 to 16 years,...



